Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $259.64 USD
Change Today +1.44 / 0.56%
Volume 421.2K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 3:50 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

y technology and is designed to provide once-daily dosing. It is available in 5mg, 10mg, 15mg, 20mg, 25mg and 30mg capsules. The FDA approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD in 2001, for adults in 2004 and for adolescents aged 13 to 17 in 2005. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in 2009. The company receives royalties from Impax’s sales of authorized generic ADDERALL XR. The company’s supply obligations to Impax ended September 30, 2014. The company has extended its supply agreement with Teva until September 30, 2016. The company has an agreement with Sandoz Inc. (Sandoz) whereby the company would supply Sandoz with an authorized generic version of ADDERALL XR beginning July 1, 2016. INTUNIV INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex. The FDA approved INTUNIV as a once-daily monotherapy treatment of ADHD in children and adolescents aged 6 to 17 and as adjunctive therapy to stimulants in 2011. It is available in 1mg, 2mg, 3mg and 4mg tablets. INTUNIV XR was approved by Health Canada as monotherapy for the treatment of ADHD in children aged 6 to 12 years and as adjunctive therapy to psychostimulants for the treatment of ADHD in children, aged 6 to 12 years, with a sub-optimal response to psychostimulants in 2013 and was launched in Canada in 2013. In 2014, the company announced the acceptance of submission of a Marketing Authorisation Application (MAA) by the European Medicines Agency (EMA) for once-daily, non-stimulant guanfacine extended release for the treatment of ADHD in children/adolescents aged 6-17 years. In 2013, the company settled outstanding litigation with Actavis Inc. and certain of its respective affiliates (Actavis) and six other abbreviated new drug applications filers regarding their respective ANDAs for INTUNIV. The settlement provides Actavis with a license to make and market Actavis’ generic versions of INTUNIV in the United States for 180 days starting on December 1, 2014. EQUASYM The company owns worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM immediate release and modified release (XL) preparations for the treatment of ADHD in children and adolescents aged 6 to 17. The company is focusing on the XL form. As of December 31, 2014, EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea by the company under the trade name METADATE CD. BUCCOLAM BUCCOLAM is the licensed oromucosal midazolam solution for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to 18 years of age) designed to be used by care givers in out of hospital settings. BUCCOLAM must only be used by parents/care givers where the patient has been diagnosed to have epilepsy. For infants 3–6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. BUCCOLAM received a positive outcome from the European Union Centralised Procedure in 2011 resulting in Marketing Authorization approvals in all EU member states. BUCCOLAM was the first Paediatric Use Marketing Authorisation (PUMA) to be approved in Europe (in 2011). BUCCOLAM is launched and marketed in the United Kingdom, Ireland, France, Nordics, Spain, Germany, Italy, Israel and Greece. BUCCOLAM is supplied in pre-filled, ready-to-use, unit-dose preparation, oral syringes. Treatments for Ulcerative Colitis (UC) UC was estimated to affect approximately 1.2 million patients in major markets (the United States and EU5). UC is a serious chronic inflammatory disease of the colon in which part or all of the large intestine becomes inflamed and often ulcerated. Typically, patients go through periods of relapse and remission and can suffer from diarrhea, bleeding and abdominal pain. On

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $259.64 USD +1.44

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$91.12 AUD -0.52
Eisai Co Ltd ¥7,965 JPY -151.00
Hospira Inc $88.33 USD +0.02
Mylan NV $69.69 USD -0.25
UCB SA €64.54 EUR +2.00
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 14.8x
Price/Sales 8.2x
Price/Book 5.7x
Price/Cash Flow 14.2x
TEV/Sales 8.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.